Nebicapone

Nebicapone (BIA 3-202), a reversible catechol-O-methyltransferase (COMT) inhibitor, is mainly metabolized by glucuronidation. Nebicapone is mainly peripherally acting inhibitor that decreases the biotransformation of L-DOPA to 3-O-methyl-DOPA by inhibition of COMT, and it is potential for the treatment of Parkinson's disease[1].

Product Specifications

CAS Number

[274925-86-9]

Product Name Alternative

BIA 3-202

UNSPSC

12352005

Target

COMT

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease; Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/nebicapone.html

Purity

99.89

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=C(C1=CC([N+]([O-])=O)=C(O)C(O)=C1)CC2=CC=CC=C2

Molecular Formula

C14H11NO5

Molecular Weight

273.24

References & Citations

[1]Loureiro AI, et al. Human metabolism of nebicapone (BIA 3-202), a novel catechol-o-methyltransferase inhibitor: characterization of in vitro glucuronidation. Drug Metab Dispos. 2006 Nov;34 (11) :1856-62.